Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. and Baylor Research Institute have reached a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC, resolving patent litigation related to the Company's DOJOLVI® (triheptanoin) oral liquid. The litigation stemmed from Esjay's submission of an Abbreviated New Drug Application seeking approval for a generic version of DOJOLVI. Under the terms, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market its generic DOJOLVI starting January 1, 2033, with a potential extension to July 1, 2033, if pediatric exclusivity is granted. Other similar patent litigations concerning DOJOLVI remain ongoing.

Ultragenyx Pharmaceutical Inc. reported a 28% increase in total revenues for the second quarter of 2026, reaching $214 million, with product sales growing 38% to $112 million. The company's net loss for the quarter narrowed to $92 million from $115 million in the prior year. However, for the six months ended June 30, 2026, the net loss increased to $277 million, and cash and cash equivalents significantly decreased to $125 million from $421 million at year-end 2025, reflecting increased cash used in operating activities.

Ultragenyx Pharmaceutical Inc. reported record second quarter 2026 total revenue of $214 million, driven by Crysvita and Dojolvi sales. The company reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million and its commitment to achieving profitability in 2027. Ultragenyx also highlighted significant upcoming catalysts, including two PDUFA dates for DTX401 and UX111, and pivotal data from the GTX-102 Phase 3 Aspire study expected in the second half of 2026. Net loss for the quarter improved to $92 million, or $0.90 per share.

Ultragenyx Pharmaceutical Inc. announced it will host a conference call on Tuesday, August 4, 2026, at 5:00 p.m. ET. The purpose of the call is to discuss the company's financial results and provide a corporate update for the quarter ending June 30, 2026. A live and replayed webcast of the call will be accessible through the company's investor relations website.

Ultragenyx Pharmaceutical Inc. reported the grant of 65,886 restricted stock units (RSUs) to 39 newly hired non-executive officers. These awards, approved by the compensation committee, were granted on July 16, 2026, under the company's Employment Inducement Plan. The RSUs are intended to induce new employees to join Ultragenyx and will vest over four years, with 25% of the shares vesting on each anniversary of the grant date, contingent on continuous employment.

Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, detailing significant progress in its corporate responsibility efforts for patients with rare diseases. The report highlights advancements in five investigational therapies, a substantial investment of 62% of operating expenses in R&D, and expanded access to approved treatments for over 700 patients in 50 countries. The company also emphasized its commitment to ESG, including $3.3 million in charitable donations and achieving nearly 100% renewable electricity for key facilities.

Ultragenyx Pharmaceutical Inc. reported the grant of 44,409 restricted stock units (RSUs) to 15 newly hired non-executive officers. These awards, approved by the compensation committee, were made under the Ultragenyx Employment Inducement Plan as an incentive for new employees. The RSUs will vest over four years, with 25% of the shares vesting on each anniversary of the June 16, 2026 grant date, contingent on continuous employment.

Ultragenyx Pharmaceutical Inc. announced that its President and CEO, Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Tuesday, June 9, 2026, at 4:00 PM ET. A live and archived webcast of the fireside chat will be accessible on the company's investor relations website.

Ultragenyx Pharmaceutical Inc. reported the grant of 17,567 restricted stock units (RSUs) of its common stock to 11 newly hired non-executive officers. These awards, approved by the compensation committee, were granted on May 16, 2026, under the Ultragenyx Employment Inducement Plan. The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, contingent on continuous employment.

Ultragenyx Pharmaceutical Inc. held its Annual Meeting of Stockholders on May 14, 2026. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting and approved the Third Amended and Restated 2023 Incentive Plan. Additionally, the selection of Ernst & Young LLP as the independent registered accounting firm for 2026 was ratified, and executive compensation was approved on an advisory basis.